Business Description
Clovis Oncology Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
C6O.Germany0A7C.UKCLVSQ.USA IPO Date
2011-11-16Description
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.09 | |||||
| Equity-to-Asset | -1.21 | |||||
| Debt-to-Equity | -1.63 | |||||
| Debt-to-EBITDA | -3.25 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -16.28 | |||||
| Beneish M-Score | -3.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.1 | |||||
| 3-Year EBITDA Growth Rate | 34 | |||||
| 3-Year EPS without NRI Growth Rate | 31.3 | |||||
| 3-Year FCF Growth Rate | 41 | |||||
| Future 3-5Y Total Revenue Growth Rate | -1.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.48 | |||||
| 9-Day RSI | 41.76 | |||||
| 14-Day RSI | 43.31 | |||||
| 6-1 Month Momentum % | -90.79 | |||||
| 12-1 Month Momentum % | -93.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.14 | |||||
| Quick Ratio | 0.12 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 138.47 | |||||
| Days Sales Outstanding | 64.74 | |||||
| Days Payable | 228.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -34.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.21 | |||||
| Operating Margin % | -155.38 | |||||
| Net Margin % | -189.37 | |||||
| ROA % | -57.99 | |||||
| ROIC % | -50.53 | |||||
| ROC (Joel Greenblatt) % | -889.77 | |||||
| ROCE % | -115.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.14 | |||||
| EV-to-EBIT | -2.93 | |||||
| EV-to-EBITDA | -3.04 | |||||
| EV-to-Revenue | 4.79 | |||||
| EV-to-Forward-Revenue | 4.77 | |||||
| EV-to-FCF | -3.6 | |||||
| Earnings Yield (Greenblatt) % | -34.13 |
How Clovis Oncology Inc (CLVSQ) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CLVSQ
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 133.021 | ||
| EPS (TTM) ($) | -1.82 | ||
| Beta | -0.23 | ||
| Volatility % | 257.43 | ||
| 14-Day RSI | 43.31 | ||
| 14-Day ATR ($) | 0.022719 | ||
| 20-Day SMA ($) | 0.114783 | ||
| 12-1 Month Momentum % | -93.82 | ||
| 52-Week Range ($) | 0.0422 - 3.25 | ||
| Shares Outstanding (Mil) | 144.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clovis Oncology Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clovis Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Clovis Oncology Inc Frequently Asked Questions
What is Clovis Oncology Inc(CLVSQ)'s stock price today?
The current price of CLVSQ is $0.09. The 52 week high of CLVSQ is $3.25 and 52 week low is $0.04.
When is next earnings date of Clovis Oncology Inc(CLVSQ)?
The next earnings date of Clovis Oncology Inc(CLVSQ) is 2023-05-04 Est..
Does Clovis Oncology Inc(CLVSQ) pay dividends? If so, how much?
Clovis Oncology Inc(CLVSQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
